05:11 AM EDT, 08/17/2026 (MT Newswires) -- Dicot Pharma (DICOT.ST) submitted an application to conduct a phase 2b clinical trial of its erectile dysfunction drug candidate LIB-01 in the European Union. The Swedish pharmaceutical company expects a decision in the fourth quarter, according to a Monday release. It plans to initiate the first part of the study in the US in the second half after securing approval from the US Food and Drug Administration in June. The phase 2b study, which will involve at least 200 participants, is intended to investigate the drug candidate's efficacy in repeated doses to determine the dose for the late-stage trial.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.